Japan Docetaxel Market Size & Outlook, 2025-2030
Related Markets
Japan docetaxel market highlights
- The Japan docetaxel market generated a revenue of USD 66.6 million in 2024 and is expected to reach USD 97.1 million by 2030.
- The Japan market is expected to grow at a CAGR of 6.6% from 2025 to 2030.
- In terms of segment, breast cancer was the largest revenue generating indication in 2024.
- Squamous Cell Carcinoma of the Head and Neck is the most lucrative indication segment registering the fastest growth during the forecast period.
Docetaxel market data book summary
| Market revenue in 2024 | USD 66.6 million |
| Market revenue in 2030 | USD 97.1 million |
| Growth rate | 6.6% (CAGR from 2025 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Squamous Cell Carcinoma of the Head and Neck |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Hormone Refractory Prostate Cancer, Gastric Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck |
| Key market players worldwide | Phyton Biotech, Rochem, Alchem International, LGM Pharma, HRV Global LifeSciences, Teva Active Pharmaceutical Ingredients, Arch Pharmalabs, Aspen Pharmacare, Cipla Ltd DR |
Other key industry trends
- In terms of revenue, Japan accounted for 5.3% of the global docetaxel market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan docetaxel market is projected to lead the regional market in terms of revenue in 2030.
- Japan is the fastest growing regional market in Asia Pacific and is projected to reach USD 97.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Docetaxel Market Scope
Docetaxel Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Teva Active Pharmaceutical Ingredients | View profile | 5001-10000 | http://www.tapi.com/ | |
| HRV Global LifeSciences | View profile | 101-250 | Hyderabad, Andhra Pradesh, India, Asia | https://hrvglobal.com |
| Alchem International | View profile | 11-50 | Delhi, Delhi, India, Asia | https://www.alchemlife.com |
| Rochem | View profile | 11-50 | Hauppauge, New York, United States, North America | https://rochemintl.com/ |
| Phyton Biotech | View profile | 51-100 | Delta, British Columbia, Canada, North America | http://www.phytonbiotech.com |
| Arch Pharmalabs | View profile | 5001-10000 | Mumbai, Maharashtra, India, Asia | http://www.archpharmalabs.com |
| Aspen Pharmacare | View profile | 10001+ | Durban, NA - South Africa, South Africa, Africa | https://www.aspenpharma.com |
| LGM Pharma | View profile | 101-250 | Nashville, Tennessee, United States, North America | https://lgmpharma.com/ |
| Cipla Ltd DR | View profile | 38955 | Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, India, 400 013 | https://www.cipla.com |
Japan docetaxel market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to docetaxel market will help companies and investors design strategic landscapes.
Breast cancer was the largest segment with a revenue share of 34.98% in 2024. Horizon Databook has segmented the Japan docetaxel market based on breast cancer, non-small cell lung cancer (nsclc), hormone refractory prostate cancer, gastric adenocarcinoma, squamous cell carcinoma of the head and neck covering the revenue growth of each sub-segment from 2018 to 2030.
Japan’s docetaxel market is expanding due to its aging population, high cancer screening rates, and integration of chemotherapies in national care guidelines. Government support for generics and well-structured hospital systems underpin market growth. Retail pharmacies dominate docetaxel distribution, with institutional support enhancing disease management.
Reasons to subscribe to Japan docetaxel market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan docetaxel market databook
-
Our clientele includes a mix of docetaxel market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan docetaxel market , including forecasts for subscribers. This country databook contains high-level insights into Japan docetaxel market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan Indication - Docetaxel Market size, 2024 - 2030 (US$M)
Japan Docetaxel Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
